Cargando…

106 Neisseria Meningitidis Derived Proteoliposome as an Adjuvant for Allergen Vaccines

BACKGROUND: In recent years one important trend of Allergen-specific immunotherapy is to investigate new adjuvants with immunomodulatory properties. The outer membrane vesicle or proteoliposome (PL) from Neisseria meningitidis serogroup B has been reported as a potent adjuvant inducing a Th1-skewed...

Descripción completa

Detalles Bibliográficos
Autores principales: González, Wendy Ramírez, Labrada, Alexis, Bourg, Virgilio, González, Bárbara, Torralba, Damarys, Quintero, Arelis Más, Pérez, Oliver, Lastre, Miriam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: World Allergy Organization Journal 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3512719/
http://dx.doi.org/10.1097/01.WOX.0000411851.07299.2a
_version_ 1782251785984933888
author González, Wendy Ramírez
Labrada, Alexis
Bourg, Virgilio
González, Bárbara
Torralba, Damarys
Quintero, Arelis Más
Pérez, Oliver
Lastre, Miriam
author_facet González, Wendy Ramírez
Labrada, Alexis
Bourg, Virgilio
González, Bárbara
Torralba, Damarys
Quintero, Arelis Más
Pérez, Oliver
Lastre, Miriam
author_sort González, Wendy Ramírez
collection PubMed
description BACKGROUND: In recent years one important trend of Allergen-specific immunotherapy is to investigate new adjuvants with immunomodulatory properties. The outer membrane vesicle or proteoliposome (PL) from Neisseria meningitidis serogroup B has been reported as a potent adjuvant inducing a Th1-skewed response. The aim of this work was to assess the immunogenicity of a novel anti-allergic vaccine candidate based on purified allergens from Dermatophagoides siboney mite and PL as adjuvant, both components adsorbed onto Aluminum hydroxide. METHODS: In a preventative experimental setting BALB/c mice were administered with 3 doses containing 5 μg of Der s 1 allergen at one week intervals by subcutaneous route. Further, mice were subjected to allergen challenge by aerosol inhalation. In another experiment, mice were administered first with 2 doses of PL + Alum and later with the whole vaccines formulation, including the allergen. The allergen-specific antibody response was assessed determining serum levels of IgE, IgG1, and IgG2a by ELISA. The local allergic inflammatory response was evaluated by measuring cytokine levels (IL-4, IL-5, IFNg and IL-10) in broncho-alveolar lavage (BAL) by ELISA. RESULTS: The formulation consistently induced IgG2a, as well as IgG1 antibodies with a potential anti-IgE blocking effect. The induction of IgG2a was clearly PL dependent while IgG1 was dependent mostly of Alum. Prior administration of the proteoliposome with alum without allergen showed to enhance this allergen-specific immunogenic effect. The vaccine prevented the development of systemic (IgE) and local allergic response in mice subjected to allergen exposure by inhalant route. Vaccinated mice showed lower levels of serum IgE, Th2 cytokines (IL-4, IL-5) in BAL and lower eosinophil counting in blood as compared to controls. Histological examination of lungs showed also a diminished allergic inflammatory response in vaccinated mice in contrast with mice which were administered with the conventional formulation of Alum-adsorbed allergen. CONCLUSIONS: The antiallergic protective effect was proven in a preventative setting, showing to decrease the inflammatory response in the lungs of mice exposed to allergen aerosol, as well as, a Th2-antagonistic immune response with few injections.
format Online
Article
Text
id pubmed-3512719
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher World Allergy Organization Journal
record_format MEDLINE/PubMed
spelling pubmed-35127192012-12-21 106 Neisseria Meningitidis Derived Proteoliposome as an Adjuvant for Allergen Vaccines González, Wendy Ramírez Labrada, Alexis Bourg, Virgilio González, Bárbara Torralba, Damarys Quintero, Arelis Más Pérez, Oliver Lastre, Miriam World Allergy Organ J Abstracts of the XXII World Allergy Congress BACKGROUND: In recent years one important trend of Allergen-specific immunotherapy is to investigate new adjuvants with immunomodulatory properties. The outer membrane vesicle or proteoliposome (PL) from Neisseria meningitidis serogroup B has been reported as a potent adjuvant inducing a Th1-skewed response. The aim of this work was to assess the immunogenicity of a novel anti-allergic vaccine candidate based on purified allergens from Dermatophagoides siboney mite and PL as adjuvant, both components adsorbed onto Aluminum hydroxide. METHODS: In a preventative experimental setting BALB/c mice were administered with 3 doses containing 5 μg of Der s 1 allergen at one week intervals by subcutaneous route. Further, mice were subjected to allergen challenge by aerosol inhalation. In another experiment, mice were administered first with 2 doses of PL + Alum and later with the whole vaccines formulation, including the allergen. The allergen-specific antibody response was assessed determining serum levels of IgE, IgG1, and IgG2a by ELISA. The local allergic inflammatory response was evaluated by measuring cytokine levels (IL-4, IL-5, IFNg and IL-10) in broncho-alveolar lavage (BAL) by ELISA. RESULTS: The formulation consistently induced IgG2a, as well as IgG1 antibodies with a potential anti-IgE blocking effect. The induction of IgG2a was clearly PL dependent while IgG1 was dependent mostly of Alum. Prior administration of the proteoliposome with alum without allergen showed to enhance this allergen-specific immunogenic effect. The vaccine prevented the development of systemic (IgE) and local allergic response in mice subjected to allergen exposure by inhalant route. Vaccinated mice showed lower levels of serum IgE, Th2 cytokines (IL-4, IL-5) in BAL and lower eosinophil counting in blood as compared to controls. Histological examination of lungs showed also a diminished allergic inflammatory response in vaccinated mice in contrast with mice which were administered with the conventional formulation of Alum-adsorbed allergen. CONCLUSIONS: The antiallergic protective effect was proven in a preventative setting, showing to decrease the inflammatory response in the lungs of mice exposed to allergen aerosol, as well as, a Th2-antagonistic immune response with few injections. World Allergy Organization Journal 2012-02-17 /pmc/articles/PMC3512719/ http://dx.doi.org/10.1097/01.WOX.0000411851.07299.2a Text en Copyright © 2012 by World Allergy Organization
spellingShingle Abstracts of the XXII World Allergy Congress
González, Wendy Ramírez
Labrada, Alexis
Bourg, Virgilio
González, Bárbara
Torralba, Damarys
Quintero, Arelis Más
Pérez, Oliver
Lastre, Miriam
106 Neisseria Meningitidis Derived Proteoliposome as an Adjuvant for Allergen Vaccines
title 106 Neisseria Meningitidis Derived Proteoliposome as an Adjuvant for Allergen Vaccines
title_full 106 Neisseria Meningitidis Derived Proteoliposome as an Adjuvant for Allergen Vaccines
title_fullStr 106 Neisseria Meningitidis Derived Proteoliposome as an Adjuvant for Allergen Vaccines
title_full_unstemmed 106 Neisseria Meningitidis Derived Proteoliposome as an Adjuvant for Allergen Vaccines
title_short 106 Neisseria Meningitidis Derived Proteoliposome as an Adjuvant for Allergen Vaccines
title_sort 106 neisseria meningitidis derived proteoliposome as an adjuvant for allergen vaccines
topic Abstracts of the XXII World Allergy Congress
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3512719/
http://dx.doi.org/10.1097/01.WOX.0000411851.07299.2a
work_keys_str_mv AT gonzalezwendyramirez 106neisseriameningitidisderivedproteoliposomeasanadjuvantforallergenvaccines
AT labradaalexis 106neisseriameningitidisderivedproteoliposomeasanadjuvantforallergenvaccines
AT bourgvirgilio 106neisseriameningitidisderivedproteoliposomeasanadjuvantforallergenvaccines
AT gonzalezbarbara 106neisseriameningitidisderivedproteoliposomeasanadjuvantforallergenvaccines
AT torralbadamarys 106neisseriameningitidisderivedproteoliposomeasanadjuvantforallergenvaccines
AT quinteroarelismas 106neisseriameningitidisderivedproteoliposomeasanadjuvantforallergenvaccines
AT perezoliver 106neisseriameningitidisderivedproteoliposomeasanadjuvantforallergenvaccines
AT lastremiriam 106neisseriameningitidisderivedproteoliposomeasanadjuvantforallergenvaccines